Sanofi eyes German insulin investment of up to $1.6 bln, source says
Adds context on French politics in fourth paragraph, details on Novo Nordisk in paragraphs 8 and 9
BERLIN, July 1 (Reuters) -French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.
The expected investment would be the latest in a string of recent wins by Germany's ruling coalition to attract foreign investments, particularly in the pharmaceuticals sector.
German newspaper Handelsblatt, which first reported the investment plan on Monday, cited German government sources as saying Sanofi had changed course after initially considering shifting production of its insulin brand Lantus to France, and was now close to committing to an upgrade of its German site in Frankfurt's Hoechst district.
Sanofi's possible expansion in Germany comes as France's far-right National Rally scored major wins in the first round of parliamentary elections, fuelling uncertainty over what a potential shift in political power could mean for business, though the source did not mention political factors as possible influences and gave no reason for favouring Germany.
The company said it would not comment on specific investment projects. A German government spokesperson said Chancellor Olaf Scholz was "very much looking forward" to further developments but it was for the company to provide an update.
Among recent wins by Germany's ruling coalition in attracting healthcare investments, Daiichi Sankyo 4568.T said in February it would spend about 1 billion euros to boost its work on precision cancer drugs near Munich.
U.S. drugmaker Eli Lilly LLY.N in November last year pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany.
The world's other largest insulin maker, Novo Nordisk NOVOb.CO, meanwhile, has recently showed signs of prioritising manufacturing of its blockbuster obesity drug Wegovy, and diabetes drug Ozempic, which contains the same active ingredient, over the production of insulin.
In November for example Novo announced it would discontinue one of its insulins, Levemir, citing manufacturing constraints among other issues.
Scholz's coalition government, whose three constituent parties suffered big losses in European elections last month, is eager to bolster its economic credentials ahead of general elections next year.
Europe's biggest economy is expected to return to growth of 0.3% to 0.4% this year, after a 0.3% contraction in 2023, which was the weakest performance among big euro zone countries.
But foreign companies announced record levels of new investment in Germany last year despite the downturn and high energy prices, a report showed in May.
Reporting by Klaus Lauer in Berlin; Additional reporting by Maggie Fick; Writing by Ludwig Burger and Christoph Steitz; Editing by Susan Fenton and David Holmes
Actifs liés
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.
